Define clinical exposure associated with QTc liability

Data Card

Early cardiac derisking: A clinically translatable hiPSC cardiomyocyte assay

Achieve action potential recordings from intrinsically paced hiPSC-CMs with Metrion’s clinically predictive hiPSC cardiomyocyte assay.

Simultaneous high-resolution measurement across 96 well plate at 10,000 Hz
Recordings using voltage-sensitive dye equivalent in quality to patch clamp
Multiple endpoints evaluated (APD20/50/90, rise time, beat rate, triangulation)
Measurement of acute (30min) and chronic (24h/48h) effects
Predicts clinical exposure associated with 10ms QTc prolongation
Defines exposure associated with QRS probability
Highlights unknown acute/chronic toxicity

Contact us for a quote or discussion

Recommended Publications

Latest Publications

Simultaneous assessment of current response and ΔV½ enables sensitive characterisation of KV7 modulators across screening and profiling workflows

By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity

Robust Kv7 voltage gated potassium ion channel profiling for confident compound selection

By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity

View All

Activation of TREK-1 and TREK-2 Two-Pore Domain Potassium Channels by the Kv4 Channel Modulator, NS5806

Future-proof cardiac safety: Scalable hiPSC cardiomyocyte new approach methodologies (NAMs) that de-risk earlier and strengthen IND packages

View All